Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04911478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Study sites revised (5)
    v4
  2. Start date changed from estimate of Aug 2021 to Feb 14, 2022v3 Show 5 more changesShow less
    • Primary endpoint revised
    • Secondary endpoints revised (8)
    • Eligibility criteria expanded, about 1 word
    • Study description shortened, about 4 words
    • Study title shortened, about 2 words
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Site contacts updated at 5 of 5 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Adicet Therapeutics
5 trials monitored
See 1 trial at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
DLBCL
703 trials monitored
See 44 trials at risk
Follicular Lymphoma
347 trials monitored
See 28 trials at risk
and 1 more disease
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
Trial Details
NCT Number NCT04911478
Lead Sponsor Adicet Therapeutics
Conditions
(from sponsor)		 Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Related terms Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov